STAMFORD, Conn.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq:DCTH) announces the expansion of the Company’s Phase II multi-histology clinical trial to include a fourth arm consisting of patients with metastatic melanoma in the liver who have previously received isolated hepatic perfusion (IHP), but whose cancer has since relapsed. The Phase II clinical trial, which is ongoing at the National Cancer Institute (NCI), is testing use of the Delcath System for the organ-specific delivery of the chemotherapeutic agent, melphalan, in patients with specific tumors in the liver, including primary liver cancer, metastatic neuroendocrine tumors and adenocarcinomas in the liver.
